ProCE Banner Activity

PROFILE 1001: Crizotinib in Advanced Non-Small-Cell Lung Cancer With MET Exon 14 Alterations

Slideset Download
Conference Coverage
Crizotinib shows antitumor activity, with a tolerable safety profile, in NSCLC with MET exon 14 alterations.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals